3,234 Shares in CVRx, Inc. (NASDAQ:CVRX) Bought by Federated Hermes Inc.

Federated Hermes Inc. purchased a new position in shares of CVRx, Inc. (NASDAQ:CVRX) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 3,234 shares of the company’s stock, valued at approximately $102,000.

Several other institutional investors have also bought and sold shares of the stock. Kestra Advisory Services LLC acquired a new position in CVRx in the third quarter worth $462,000. Schonfeld Strategic Advisors LLC grew its holdings in CVRx by 47.2% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 59,900 shares of the company’s stock worth $909,000 after acquiring an additional 19,200 shares during the last quarter. GSG Advisors LLC acquired a new stake in CVRx in the 3rd quarter valued at about $2,435,000. Lord Abbett & CO. LLC bought a new position in shares of CVRx in the third quarter worth about $7,116,000. Finally, Emerald Advisers LLC lifted its position in shares of CVRx by 1.3% during the third quarter. Emerald Advisers LLC now owns 501,073 shares of the company’s stock worth $7,601,000 after purchasing an additional 6,419 shares in the last quarter. Institutional investors and hedge funds own 75.27% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on CVRX. Piper Sandler dropped their price objective on shares of CVRx from $33.00 to $15.00 and set an “overweight” rating for the company in a research report on Wednesday, May 1st. Canaccord Genuity Group dropped their target price on CVRx from $32.00 to $14.00 and set a “buy” rating for the company in a research report on Wednesday, May 1st. Lake Street Capital decreased their price target on CVRx from $35.00 to $18.00 and set a “buy” rating on the stock in a report on Wednesday, May 1st. Craig Hallum started coverage on CVRx in a report on Wednesday, May 1st. They set a “buy” rating and a $23.00 price objective for the company. Finally, JPMorgan Chase & Co. lowered shares of CVRx from an “overweight” rating to a “neutral” rating and reduced their target price for the company from $36.00 to $13.00 in a research note on Wednesday, May 1st. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $16.60.

CVRx Trading Down 13.6 %

CVRX stock opened at $7.97 on Tuesday. The company has a fifty day moving average price of $17.85 and a two-hundred day moving average price of $20.98. The company has a debt-to-equity ratio of 0.38, a current ratio of 14.25 and a quick ratio of 12.86. The stock has a market cap of $172.11 million, a price-to-earnings ratio of -3.23 and a beta of 1.35. CVRx, Inc. has a one year low of $7.77 and a one year high of $33.13.

Insider Transactions at CVRx

In other news, insider Paul Verrastro sold 2,545 shares of CVRx stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $21.91, for a total transaction of $55,760.95. Following the completion of the sale, the insider now owns 2,455 shares of the company’s stock, valued at $53,789.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, insider Paul Verrastro sold 2,545 shares of the business’s stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $21.91, for a total value of $55,760.95. Following the completion of the transaction, the insider now owns 2,455 shares of the company’s stock, valued at $53,789.05. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the sale, the insider now directly owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The disclosure for this sale can be found here. 18.30% of the stock is owned by corporate insiders.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.